University of British Columbia

Centre for Drug Research and Development

Other

Angiotech Pharmaceuticals, Inc.

Helen M Burt

John K Jackson

Martin E Gleave

Rajesh Kumar Kainthan

Donald Elliott Brooks

Jayachandran N Kizhakkedathu

Richard Tom Liggins

Dechi Guan

Clement Mugabe

Alan So

Lu Ye

Stephen K Dordunoo

William L Hunter

Lindsay Stuart Machan

A Larry Arsenault

Jason Zastre

John J Jackson

Herein are provided derivatized hyperbranched polyglycerols ('dHPGs'). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with CCalkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

Derivatized hyperbranched polyglycerols

Topoisomerase inhibitors are useful for the treatment of inflammatory disorders including arthritis, restenosis, surgical adhesions and other diseases. Controlled release polymeric formulations to topoisomerase inhibitors are particularly suitable for this use.

Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Anti-angiogenic nanoparticle compositions

This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient.

Micellar drug delivery systems for hydrophobic drugs

Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.

Pharmaceutical compositions and methods relating to fucans

Growing community of inventors

Vancouver, Canada

Helen M Burt